Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Femasys ( (FEMY) ) has shared an update.
On July 1, 2025, Femasys Inc. announced the achievement of regulatory approvals in Australia and New Zealand for its infertility solutions, FemaSeed for first-line intratubal insemination treatment and FemVue for diagnostic evaluation. These approvals mark a significant milestone in expanding global access to Femasys’ innovative infertility solutions, validating the clinical value of their platform and creating meaningful commercial opportunities. This development reinforces Femasys’ commitment to providing accessible, first-line infertility solutions, addressing critical gaps in care for women struggling with infertility.
The most recent analyst rating on (FEMY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.
Femasys’ overall stock score is primarily impacted by its challenging financial performance and valuation. While technical analysis shows neutral sentiment, significant corporate events, such as the European approval for FemBloc and the Nasdaq delisting notice, present both opportunities and risks. Strengthening financial health and market compliance are critical for future stability.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Femasys Inc. is a leading biomedical innovator focused on addressing critical unmet needs in women’s health. The company offers a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. Femasys is actively commercializing its lead product innovations, including FemaSeed Intratubal Insemination and FemVue diagnostic for fallopian tube assessment, in the U.S. and key international markets.
Average Trading Volume: 317,586
Technical Sentiment Signal: Strong Sell
Current Market Cap: $28.57M
See more data about FEMY stock on TipRanks’ Stock Analysis page.